Canberra Hospital is a major tertiary public hospital located in Garran, Canberra, Australian Capital Territory. It is the largest hospital in the region with 672 beds catering to a population of about 550,000.

There are 672 beds in Canberra Hospital.

During the past decade, Canberra Hospital conducted 57 clinical trials. In the 10-year time frame, 57 clinical trials started and 36 clinical trials were completed, i.e. on average, 63.2% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 25 clinical trials were completed. i.e. 113.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Canberra Hospital" #1 sponsor was "Pfizer" with 6 trials, followed by "Celgene" with 5 trials sponsored, "BeiGene" with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "Biotronik SE & Co. KG" with 4 trials sponsored. Other sponsors include 73 different institutions and companies that sponsored additional 66 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Canberra Hospital" #1 collaborator was "National Health and Medical Research Council, Australia" with 5 trials as a collaborator, "Australasian Leukaemia and Lymphoma Group" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator and "Roche Pharma AG" with 2 trials as a collaborator. Other collaborators include 90 different institutions and companies that were collaborators in the rest 100 trials.

According to Clinical.Site data, the most researched conditions in "Canberra Hospital" are "Ulcerative Colitis" (5 trials), "Acute Myeloid Leukemia" (4 trials), "Heart Failure" (4 trials), "Lymphoma" (4 trials) and "Crohn Disease" (3 trials). Many other conditions were trialed in "Canberra Hospital" in a lesser frequency.

Most popular intervention types in "Canberra Hospital" are "Drug" (76 trials), "Other" (11 trials), "Procedure" (9 trials), "Biological" (7 trials) and "Device" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Rituximab" (7 trials), "Bendamustine" (4 trials), "rituximab" (4 trials) and "Etrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Canberra Hospital" are 95 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Canberra Hospital". undefined are not yet recruiting, 21 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 57 completed trials in Canberra Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Canberra Hospital, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 11 trials that are defined as “Not Applicable".

Canberra Hospital has several departments that took part in Clinical trials: "Canberra Hospital; Medical Oncology" - 2 trials, "Canberra Hospital; Haematology Department" - 2 trials